Antitumor activity of interleukin-12 against murine bladder cancer

Masatoshi Eto, Mamoru Harada, Koji Tamada, Noriaki Tokuda, Yasuhiro Koikawa, Motonobu Nakamura, Kikuo Nomoto, Seiji Naito

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.

Original languageEnglish
Pages (from-to)1549-1552
Number of pages4
JournalJournal of Urology
Issue number5
Publication statusPublished - May 2000

All Science Journal Classification (ASJC) codes

  • Urology


Dive into the research topics of 'Antitumor activity of interleukin-12 against murine bladder cancer'. Together they form a unique fingerprint.

Cite this